Emerald Health Therapeutics to Attend Global Cannabis Conference Hosted by Eight Capital & Cassels Brock – Acquire Marihuana Website Calgary Canada

Avis BioSpiruline.fr
4.6 / 5 - 1329 Avis
Class in: Sant
Subject : Calendar of events

VANCOUVER, British Columbia, Sept. 16, 2019 (GLOBE NEWSWIRE) – Emerald Health Therapeutics, Inc. (meraude) (TSXV: EMH, OTCQX: EMHTF) today announced its participation in a panel and its availability for a meeting at from the world conference on cannabis organized by Eight Capital & Cassels Brock on September 19, 2019, the Shangri-La Hotel Toronto.

The details of the panel are as follows:

  • presenter: Allan Rewak, Vice President of Communications and Stakeholder Relations
  • Title of the panel:Use by adults, birthday date: lessons learned and opportunities coming
  • Dated:Thursday, September 19, 2019
  • Hour: 10: 00-10: 30 AM AND
  • Location:Shangri-La Hotel Toronto; Queen's Park Ballroom

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis-based products. Its strategic initiatives are focused on developing differentiated value-added products for medical and adult customers, supported by new intellectual property, large-scale culture, glue retrieval and encapsulation, as well as marketing channels. and unique distribution. Pure Sunfarms' facilities, 50% owned in British Columbia, have achieved a total annual production of approximately 75,000kg at the facilities of their first Delta3 greenhouse of 1.1 million square meters. A second 10.22 hectare greenhouse is expected to be in full production by the end of 2020. The two facilities are 100% owned by Emerald, a high quality greenhouse and processing facility in Qubec. a biological greenhouse and an open-air facility in British Columbia have started production and are working toward final expansion of their licenses. Emerald has also contracted approximately 485.6 hectares (1200 acres) of hemp each year from 2019 to 2022 for the purpose of extracting low-cost CBD. His team has extensive experience in life sciences, product development, large scale agribusiness and marketing.

Please visit www.emeraldhealth.com for more information or contact:

Rob Hill, Chief Financial Officer
(800) 757 3536 Extension n5
Emerald Investor Relations
(800) 757 3536 Post n5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its regulator (as that term is defined in the policies of the TSX Venture Exchange) assumes the responsibility for the adequacy or accuracy of this release.

Caution regarding forward-looking statements: Certain statements made in this press release, which are not historical facts, are forward-looking statements and are subject to significant risks, uncertainties and assumptions, both general and specific, which suggest that the actual results or events could differ materially from our expectations expressed or implied by the said forward-looking statements. These include obtaining regulatory approvals, production and processing capabilities of various facilities, expansion of facilities, obtaining additional crop permits and other permits, production at various facilities, receiving deliveries of hemp, the signing of strategic agreements, the payment of amounts due by, and due to, Emerald, the transplantation of crops, the obtaining of final municipal approvals, the evaluation of cultivation and harvesting techniques, the production of cannabis, excellent quality, low cost and large scale, as well as expected production costs.

We can not guarantee that forward-looking statements will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes in legislation and regulations; changes of government; the inability to obtain regulatory approvals or permits; the inability to obtain the necessary funding; the results of production and sales activities; the results of scientific research; regulatory changes; changes in prices and costs of inputs; the demand for labor; the demand for products; the failure of counterparties to fulfill their contractual obligations; as well as the risk factors described in the Company's annual information form and other regulatory documents. The forward-looking statements contained in this news release represent our expectations as of the date of this news release. The forward-looking statements are intended to provide information about management's current expectations and plans and to provide investors and others with a better understanding of our intended operating environment. Readers are reminded that this information may not be relevant for other purposes. The Company assumes no obligation to update or revise such statements to reflect new or unexpected circumstances as they occur, except as required by applicable law.

These releases may interest you as well

9:00

A new survey commissioned by AGE-WELL, a federal government-funded network of centers of excellence, and led by Environics Research, provides new insights into the attitudes of Canadians over 65 and 50 to 64 years of age.

8:40

Emerald Health Therapeutics, Inc. (meraude) today announced its participation in a panel and its availability for a meeting at the global cannabis conference hosted by Eight Capital & Cassels Brock on September 19, 2019, …

8:00

Oncoheroes Biosciences Inc. (Oncoheroes) and Boehringer Ingelheim International GmbH (Boehringer Ingelheim) have signed an exclusive worldwide license agreement for volasertib, an experimental anti-cancer compound that has been discovered and put into practice by the …

8:00

Five Ontario members of the Royal Canadian Mounted Police (RCMP) will be participating in the Fundraising Campaign for theCancerCancer Program, which is starting today at the Niagara Regional Police Headquarters.

7:12

Porsolt SAS, a well-established clinical research organization (CRO) established in the field of preclinical screening, efficacy and safety, is expanding its research center and has just completed an extension of the …

7:00

Representatives of the media are invited to attend the opening of the new living spaces of the CHSLD du Roseau, Victoriaville. The activity will take place in the presence of the Minister responsible for the Answers and caregivers, …

Communiqu sent on 16 September 2019 08:40 and distributed by:

Here’s what you want to know before seeing your local medical dispensary:You will need a physician’s recommendation, medical cannabis certificate, or whatever appropriate documentation is needed by your condition. Ordinarily, you need to be 18 or older to qualify for a medical consent, but exceptions may be made in some states for minors with particularly debilitating problems. You will often register with a medicinal dispensary. This is to keep your medical cannabis recommendation or certification on file for regulatory and legal purposes. There will be a waiting space. This is to control the flow of patients and product, but a simple dividing wall also gives patients solitude and direct one-on-one contact with a budtender to discuss medical issues. Many times, but not necessarily, your purchases will be monitored by medical dispensaries. This process can assist budtenders and patients track effective medicine as well as possess a living listing of producers and products for future reference and follow-up. Medicinal dispensaries usually permit you to smell and analyze the buds before buy. This may vary from state-to-state.

DOES AN APPLICANT NEED MUNICIPAL APPROVAL BEFORE RECEIVING A RETAIL CANNABIS LICENSE? Yes, municipal approval is necessary before the AGLC will subject a retail cannabis license. Applicants should get in touch with their intended municipality to learn requirements concerning municipal retail cannabis laws, zoning requirements, land-use limitations, and place requirements concerning how near a retail store is into a provincial medical care centre, school, or parcel of land designated as a school reserve.
Keep non-medical cannabis legal Adults that are 19 decades or older are in a position to:Possess up to 30 g of legal dried cannabis or the equivalent on their own person. Share up to 30 gram of legal cannabis with other adults in Canada. Purchase cannabis products from a Yukon Liquor Corporation licensed retailer. Grow up to four plants per family. It’s illegal to present non invasive cannabis to anyone below the age of 19 and also for anybody below the age of 19 to possess any quantity of non-medical cannabis in Yukon.It is illegal and dangerous to drive while under the influence of cannabis or other intoxicants.